Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > New Moniker Contest for Dripping Snot!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(39)
•••
Post by Yellowknifer69on Sep 11, 2020 11:59am
172 Views
Post# 31542785

New Moniker Contest for Dripping Snot!

New Moniker Contest for Dripping Snot!Okay folks

Wrapping up a Friday work week and what the hell - time for a naming contest?

The challenge:  A new Moniker for Dripping Snot

The Rules:  Must be respectful
                   Should reflect his (maybe her - I doubt it) Passion for Antibe
                   Name with the most votes wins the day
                    Dripping Snot gets a fond farewell

And the winner receives a Thumbs up from all BB contributors?  What say you Dripping Snot?  Like the idea?  Anyway, my new nickname for you is "

Prayer for Bayer - come on - its got a nice ring to it!

All right, sayonara to all the longs - hope you make it a great weekend!

Yellowknifer

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities